Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin added to neoadjuvant chemoradiotherapy for stage II-III rectal adenocarcinoma
IRCT20250223064832N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin in rectal adenocarcinoma and rectal cancer (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pathological Complete Response, Tumor Regression Grade and 1 more. Started Jul 2021; status: completed.
02
Drugs
aspirin
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on IRCT20250223064832N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250223064832N1.